3 Stocks Showing Breakout Potential Ahead of August
Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.

Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.


Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.

Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investor litigation firm [url="]Kaskela Law[/url] announces that it is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) (âIntegraâ) on beha

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Integra LifeSciences Holdings Corp. (NASDAQ: IART) (“Integra”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/cases/integra-lifesciences/ Recently a securities fraud complaint was filed against Integra on behalf of investors who purchased shares of the company's stock between March 11, 2019 and May 22, 2023 (the “Wrongdoing Period”.

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open.

Integra LifeSciences has climbed 52.1% in a year as growth across both segments, improved execution and transformation efforts continue to boost results.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Integra (IART) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?

Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution. Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution.

On June 30, 2026, Integra Lifesciences Holdings Corp (IART) shares fell 4.2% to $17.98, amid a 52-week trading range of $8.70 to $18.92. This decline comes desp

MITT, SVM and IART stand out as broker rating upgrades, earnings growth forecasts and screen criteria point to potential upside.

PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (Nasdaq: IART), a global leader in medical technology, today announced several leadership appointments within its commercial organization.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Integra (IART) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Integra LifeSciences specializes in neuro-related surgical devices and regenerative tissue technologies. The tissue reconstruction segment, featuring collagen-based products like Integra Skin and PriMatrix, is positioned as IART's primary future earnings driver. IART suffered significant earnings declines and a 75% share price drop due to FDA-related product recalls and operational lapses at its Boston facility.

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY). But which of these two stocks is more attractive to value investors?

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and president Tissue Reconstruction will present at the 2026 Truist Securities MedTech Conference on June 16, 2026 at 3:00pm ET.

PRINCETON, N. J. , June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Bob Davis, executive vice president and president Tissue Reconstruction will present at the 2026 Truist Securities MedTech Conference on June 16, 2026 at 3:00pm ET.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Integra (IART) reported earnings 30 days ago. What's next for the stock?

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?

PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026 at 10:30am ET.

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

These four GARP stocks combine discounted PEG ratios with strong growth potential, offering investors a balanced strategy for 2026.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Masimo (MASI). But which of these two stocks presents investors with the better value opportunity right now?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Integra LifeSciences NASDAQ: IART is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief executive officer, Chief Financial Officer Lea Knight said during a Bank of America med tech conference discussion hosted by analyst Rei Tan.

Integra LifeSciences Holdings Corporation (IART) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT.

PRINCETON, N. J. , May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT.

Integra (IART) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Integra LifeSciences Holdings Corporation (IART) Q1 2026 Earnings Call Transcript

The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Integra LifeSciences (IART) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.41 per share a year ago.

PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2026.

Stuart Essig Appointed as Integra's Next President and Chief Executive Officer Michael McBreen Appointed Chief Commercial Officer

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.